Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000479803 | SCV000572569 | likely pathogenic | not provided | 2016-12-21 | criteria provided, single submitter | clinical testing | The c.273_279delGCCCCTG variant in the TP53 gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. This variant causes a frameshift starting with codon Tryptophan 91, changes this amino acid to a Cysteine residue and creates a premature Stop codon at position 30 of the new reading frame, denoted p.Trp91CysfsX30. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. Based on currently available evidence, c.273_279delGCCCCTG is a strong candidate for a pathogenic variant. However, the possibility it could be a rare benign variant cannot be excluded. |
Labcorp Genetics |
RCV001865473 | SCV002184673 | pathogenic | Li-Fraumeni syndrome | 2020-12-04 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with TP53-related conditions. ClinVar contains an entry for this variant (Variation ID: 422961). For these reasons, this variant has been classified as Pathogenic. This sequence change creates a premature translational stop signal (p.Trp91Cysfs*30) in the TP53 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TP53 are known to be pathogenic (PMID: 20522432). |
Genome- |
RCV002289648 | SCV002582412 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2022-06-18 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV002289647 | SCV002583074 | likely pathogenic | Li-Fraumeni syndrome 1 | 2022-06-18 | criteria provided, single submitter | clinical testing |